TimesSquare Capital Management LLC Has $41.02 Million Position in Repligen Co. (NASDAQ:RGEN)

TimesSquare Capital Management LLC raised its holdings in Repligen Co. (NASDAQ:RGEN) by 14.6% in the third quarter, Holdings Channel.com reports. The fund owned 275,627 shares of the biotechnology company’s stock after acquiring an additional 35,115 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Repligen were worth $41,019,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Repligen by 30.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after buying an additional 6,705 shares during the last quarter. Swedbank AB bought a new position in shares of Repligen in the 1st quarter valued at approximately $5,518,000. Banque Pictet & Cie SA raised its stake in shares of Repligen by 74.6% in the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after acquiring an additional 14,746 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Repligen by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after purchasing an additional 21,719 shares during the last quarter. Finally, Diversified Trust Co boosted its position in Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 106 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on RGEN. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Finally, Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Price Performance

Shares of Repligen stock opened at $140.70 on Friday. The firm has a market cap of $7.88 billion, a P/E ratio of -3,517.50, a price-to-earnings-growth ratio of 4.19 and a beta of 0.96. The firm’s 50-day simple moving average is $141.56 and its 200-day simple moving average is $145.21. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.